Literature DB >> 8175973

Islet cell antibodies, but not glutamic acid decarboxylase antibodies, are decreased by plasmapheresis in patients with newly diagnosed insulin-dependent diabetes mellitus.

G Sundkvist1, W A Hagopian, M Landin-Olsson, A Lernmark, L Ohlsson, C Ericsson, J Ahlmén.   

Abstract

The effects of plasmapheresis on islet autoantibody levels, C-peptide (beta-cell function), and hemoglobin-A1c (HbA1c, metabolic control) were tested in a prospective blinded study of 18 newly diagnosed insulin-dependent diabetes mellitus (IDDM) patients randomly assigned to receive plasmapheresis (P), carried out as double filtration, or sham (S) treatment at diagnosis and 3 months thereafter. At diagnosis, 6 of 8 patients (75%) in group P and 9 of 10 patients (90%) in group S had islet cell antibodies (ICA), whereas 4 of 8 (50%) and 7 of 10 (70%) patients, respectively, had glutamic acid decarboxylase antibodies (GAD65-Ab), with no significant differences between the groups in ICA and GAD65-Ab levels. After 6 months, P patients showed significantly lower ICA levels than S patients (11 +/- 6 and 128 +/- 47 Juvenile Diabetes Foundation International Units, respectively; P < 0.02) due to an increase in ICA levels in 8 of 9 (88%) of the S patients not seen in P patients (P < 0.002). Concurrently, HbA1c stabilized in P, but not in S, patients and was significantly lower by 24 months (6.58 +/- 0.54% vs. 9.76 +/- 1.21%; P < 0.05). Moreover, fasting C-peptide increased significantly (214 +/- 11 pmol/L; P < 0.05) over the first 6 months in P. After the initial 6 months, ICA levels tended to decrease in all patients and were not detected after 60 months. GAD65-Ab levels were not influenced by plasmapheresis and, also in contrast to ICA, increased significantly (P < 0.05) in the whole study population after 60 months. In fact, 4 initially negative patients became GAD65-Ab positive after diagnosis (in 2 patients > 24 months after diagnosis). We conclude that plasmapheresis of newly diagnosed IDDM patients does not change subsequent GAD65-Ab levels, but ICA are significantly decreased with associated improved C-peptide and HbA1c levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175973     DOI: 10.1210/jcem.78.5.8175973

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

Review 1.  Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease.

Authors:  Robert S Fujinami; Matthias G von Herrath; Urs Christen; J Lindsay Whitton
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden.

Authors:  E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist
Journal:  Diabetologia       Date:  2006-05-31       Impact factor: 10.122

3.  Comparison of measurements of autoantibodies to glutamic acid decarboxylase and islet antigen-2 in whole blood eluates from dried blood spots using the RSR-enzyme linked immunosorbent assay kits and in-house radioimmunoassays.

Authors:  Anders Persson; Charlotte Becker; Ida Hansson; Anita Nilsson; Carina Törn
Journal:  Exp Diabetes Res       Date:  2010-06-03

4.  Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells.

Authors:  Francesco Vendrame; Antonello Pileggi; Elsa Laughlin; Gloria Allende; Ainhoa Martin-Pagola; R Damaris Molano; Stavros Diamantopoulos; Nathan Standifer; Kelly Geubtner; Ben A Falk; Hirohito Ichii; Hidenori Takahashi; Isaac Snowhite; Zhibin Chen; Armando Mendez; Linda Chen; Junichiro Sageshima; Phillip Ruiz; Gaetano Ciancio; Camillo Ricordi; Helena Reijonen; Gerald T Nepom; George W Burke; Alberto Pugliese
Journal:  Diabetes       Date:  2010-01-19       Impact factor: 9.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.